Effect of preservative free travoprost on proximal lacrimal drainage system using ASOCT- a clinical study

Sankara eye hospital Shimoga .0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1. Newly diagnosed glaucoma patients started on topical preservative free travoprost monotherapy (0.004%)
•2. Patients having diameter of punctum >=0.3 mm(0.3-0.5 mm) on slit lamp biomicroscopy before starting travoprost.
•3. Patients having pretreatment imaging parameters of proximal lacrimal drainage system within normal range as measured by ASOCT.

•1. Patients diagnosed with glaucoma and started on treatment earlier.
•2. History of long term ( more than 2 weeks) use of topical medications and oral medications likely to alter LDS.
•3. Patient requiring adjuvant treatment to lower IOP during the study.
•4 pretreatment abnormal imaging parameters of PLDS recorded by ASOCT.
•5. Diseases of LDS like punctal and canalicular stenosis, atresia, agenesis, canaliculitis, nasolacrimal duct Obstruction NLDO, tumours/ lesions involving the LDS.
•6. Eyelid malpositions like ectropion, entropion.
•7. Cicatrising ocular diseases likely to affect LDS like Steven Johnson Syndrome, Ocular cicatricial pemphigoid, chronic conjunctivitis etc.
•8. Any previous history of surgeries on LDS, eyelid.
•9. History of ocular trauma involving the eyelids, LDS.
•10. Previous history of ocular radiotherapy for various causes.

发起方

Sankara eye hospital Shimoga .